InfuSystem (INFU) Lytham Partners Fall 2024 Investor Conference summary

Company overview and unique value proposition

• Provides healthcare services by wrapping clinical, biomedical, logistics, and revenue cycle capabilities around third-party medical equipment, serving both patient services and device solutions segments.

• Holds over 800 payer contracts, enabling broad insurance coverage and the ability to layer new products and services into existing agreements.

• Manages the full lifecycle of medical devices from manufacturer to patient and insurance billing, handling hundreds of thousands of cases annually.

Patient services segment insights

• Oncology business is stable, profitable, and represents the majority of revenue, with a market share of roughly two-thirds.

• Pain management and wound care are growth areas, with wound care expanding through a joint venture with Sanara and new product launches.

• Wound care targets advanced wound care, value-based care, and non-traditional wounds in oncology, leveraging existing payer contracts.

• Exclusive distribution agreements for Chemo Mouthpiece and RadioDerm aim to address oral mucositis and radiodermatitis in oncology patients.

Device solutions segment and partnerships

• Device solutions focuses on selling and renting infusion pumps and consumables, with direct billing to hospitals and providers.

• Biomedical services, especially the GE agreement, have enabled a national technician network and are expected to drive future growth.

• Partnerships with Smith+Nephew and others provide device-agnostic options, mitigating supply chain risks and expanding product offerings.